Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Evaluator-blinded, Randomized, Delayed Treatment Control Group Study of the Safety and Effectiveness of HAC 20L for the Correction of Moderate to Severe Nasolabial Folds

NCT06018987 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06018987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06018987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Evaluator-blinded, Randomized, Delayed Treatment Control Group Study of the Safety and Effectiveness of HAC 20L for the Correction of Moderate to Severe Nasolabial Folds
Lead sponsor
AbbVie
Phase
Phase 2/3
Overall status
Completed
Start date
September 5, 2023
Completion date
February 3, 2025
Enrollment
61 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

nasolabial folds